Olympus, the medical endoscope manufacturer, confirmed that it is making significant progress in strengthening its quality systems in response to observations and warnings issued by the U.S. Food and Drug Administration (FDA). The company's CEO, Bob White, explained during an earnings presentation that the company has intensified remediation and improvement efforts since January to meet stringent regulatory expectations.
This update follows the issuance of a new warning letter by the FDA last October, which included findings of violations related to quality system regulations, in addition to the imposition of import alerts aimed at preventing the entry of additional models of endoscopes manufactured in Japan into the U.S. market. The warning letter included inspections conducted at six of the company's facilities in Japan, Europe, and the United States during late 2025.
Financial Impacts and History of Regulatory Reviews
The Tokyo-based company indicated that shipping restrictions and import alerts imposed by the regulatory body in June 2025 caused a financial impact of approximately 9 billion Japanese yen, equivalent to about 56 million dollars, on consolidated revenue.
It is worth noting that regulatory authorities had sent three previous warning letters to the company between 2022 and 2023, following inspections that revealed violations of quality systems and a failure to meet medical device reporting requirements. The situation escalated in 2025 to include a ban on dozens of endoscope models from entering the United States, against the backdrop of a decade-long investigation into the devices' link to medical infections.
Corrective Steps and New Management
The company's CEO, who assumed his duties in June 2025 as a former executive at Medtronic and GE HealthCare, emphasized that the current strategy relies on new leadership and specialized expertise brought in over the past year to enhance regulatory and operational efficiency.
Olympus stated that it continues to cooperate with the FDA to demonstrate the effectiveness and sustainability of the corrective actions taken, which contributes to ensuring business continuity and elevating approved safety standards.
Financial Results Amidst Regulatory Challenges
Despite regulatory challenges and ban decisions, Olympus announced a 9% increase in its revenue to reach 269.2 billion Japanese yen, equivalent to 1.68 billion dollars, during the second quarter of the fiscal year ending March 31, 2027. The company also raised its forecasts for revenue, adjusted operating margin, and adjusted earnings per share for the entire fiscal year.